A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä

Clinical feasibility of a commercially available MRI-only method for radiotherapy treatment planning of the brain




TekijätRanta Iiro, Wright Pauliina, Suilamo Sami, Kemppainen Reko, Schubert Gerald, Kapanen Mika, Keyriläinen Jani

KustantajaWILEY

Julkaisuvuosi2023

JournalJournal of Applied Clinical Medical Physics

Tietokannassa oleva lehden nimiJOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS

Lehden akronyymiJ APPL CLIN MED PHYS

Sivujen määrä11

ISSN1526-9914

eISSN1526-9914

DOIhttps://doi.org/10.1002/acm2.14044

Verkko-osoitehttps://aapm.onlinelibrary.wiley.com/doi/10.1002/acm2.14044

Rinnakkaistallenteen osoitehttps://research.utu.fi/converis/portal/detail/Publication/179995778


Tiivistelmä

Background
Advancements in deep-learning based synthetic computed tomography (sCT) image conversion methods have enabled the development of magnetic resonance imaging (MRI)-only based radiotherapy treatment planning (RTP) of the brain.

Purpose
This study evaluates the clinical feasibility of a commercial, deep-learning based MRI-only RTP method with respect to dose calculation and patient positioning verification performance in RTP of the brain. MethodsClinical validation of dose calculation accuracy was performed by a retrospective evaluation for 25 glioma and 25 brain metastasis patients. Dosimetric and image quality of the studied MRI-only RTP method was evaluated by a direct comparison of the sCT-based and computed tomography (CT)-based external beam radiation therapy (EBRT) images and treatment plans. Patient positioning verification accuracy of sCT images was evaluated retrospectively for 10 glioma and 10 brain metastasis patients based on clinical cone-beam computed tomography (CBCT) imaging.

Results
An average mean dose difference of D-mean = 0.1% for planning target volume (PTV) and 0.6% for normal tissue (NT) structures were obtained for glioma patients. Respective results for brain metastasis patients were D-mean = 0.5% for PTVs and D-mean=1.0% for NTs. Global three-dimensional (3D) gamma pass rates using 2%/2 mm dose difference and distance-to-agreement (DTA) criterion were 98.0% for the glioma subgroup, and 95.2% for the brain metastasis subgroup using 1%/1 mm criterion. Mean distance differences of In terms of dose calculation and patient positioning accuracy, the studied MRI-only method demonstrated its clinical feasibility for RTP of the brain. The results encourage the use of the studied method as part of a routine clinical workflow.


Ladattava julkaisu

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.





Last updated on 2024-26-11 at 13:00